Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating restated by Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $3.00 price objective on the stock. Needham & Company LLC's price target suggests a potential upside of 165.49% from the stock's previous close.
A number of other equities analysts also recently commented on LUCD. Cantor Fitzgerald reissued an "overweight" rating and issued a $2.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, March 26th. BTIG Research set a $2.00 price target on Lucid Diagnostics in a research report on Tuesday, March 25th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $3.40.
View Our Latest Research Report on Lucid Diagnostics
Lucid Diagnostics Price Performance
NASDAQ LUCD traded down $0.06 during trading on Friday, reaching $1.13. 842,572 shares of the company's stock traded hands, compared to its average volume of 436,823. Lucid Diagnostics has a 12-month low of $0.63 and a 12-month high of $1.80. The firm has a market cap of $102.55 million, a price-to-earnings ratio of -0.99 and a beta of 1.26. The company's 50 day simple moving average is $1.42 and its two-hundred day simple moving average is $1.07.
Hedge Funds Weigh In On Lucid Diagnostics
Several institutional investors and hedge funds have recently bought and sold shares of the company. Sargent Investment Group LLC acquired a new stake in shares of Lucid Diagnostics in the 4th quarter worth $442,000. Geode Capital Management LLC boosted its holdings in Lucid Diagnostics by 30.9% in the fourth quarter. Geode Capital Management LLC now owns 279,504 shares of the company's stock worth $229,000 after acquiring an additional 65,964 shares in the last quarter. Lido Advisors LLC boosted its holdings in Lucid Diagnostics by 40.0% in the fourth quarter. Lido Advisors LLC now owns 140,016 shares of the company's stock worth $115,000 after acquiring an additional 40,000 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Lucid Diagnostics during the fourth quarter worth about $98,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of Lucid Diagnostics during the fourth quarter valued at about $67,000. 74.01% of the stock is owned by hedge funds and other institutional investors.
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Read More
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
